Publication | Closed Access

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

MedicineCancer ManagementGynecologyLiposomal DoxorubicinCancer TreatmentOncologyRadiation OncologyThird-line TherapyGynecology OncologyMolecular OncologyPhase 3Ovarian Cancer